GLP Watchdog

altRX vs Embody

altRX has an open FDA warning letter dated June 8, 2026. Embody has none. On compounded tirzepatide injection, Embody costs $240 less a year at standing rates: $129 a month against $149 a month at altRX. It is one of two products the two sell at comparable terms.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

altRX / Embody

altRX logo

altRX

8.8/10

Featured pick (affiliate partner)

Embody logo

Embody

9.3/10

FDA warning letters
None on record
Pharmacy
  • RedRock Pharmacy503A
  • Health Warehousetype not stated
  • Precision Medicinetype not stated
  • and 1 more
Lowest standing price
$89/moCompounded semaglutide injection
$79/moCompounded semaglutide injection
States
All 50 states
All 50 states and DC
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit altRXFull review
Visit EmbodyFull review

Embody is our featured pick on this page because it is an affiliate partner: we are paid if you sign up through our link. altRX pays us nothing. The scores are computed the same way for both and are shown as computed (altRX 8.8, Embody 9.3). How we are paid

What the record shows

  1. 01

    altRX has an open FDA warning letter dated June 8, 2026. Embody has none.

  2. 02

    altRX names four pharmacies. Embody names four pharmacies.

  3. 03

    On compounded tirzepatide injection, Embody costs $240 less a year at standing rates: $129 a month against $149 a month at altRX. It is one of two products the two sell at comparable terms.

  4. 04

    Only altRX lists a price for brand-name semaglutide pen and brand-name tirzepatide pen. Only Embody lists a price for compounded oral tirzepatide.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

altRX

Embody

Compounded semaglutide injection

$89/mo

$1,068 a year

$79/moLower

$948 a year

Compounded tirzepatide injection

$149/mo

$1,788 a year

$129/moLower

$1,548 a year

Brand-name semaglutide pen

$1,149/mo

$13,788 a year

Not sold or not priced
Brand-name tirzepatide pen

$1,249/mo

$14,988 a year

Not sold or not priced
Compounded oral tirzepatide
Not sold or not priced

$329/mo

$3,948 a year

Price includes
Medication, clinician visits, shipping
Medication, clinician visits, shipping
Cancel any time
Yes, stated
Yes, stated
Minimum term
None on the monthly plan; multi-month plans are prepaid and non-refundable
None on the one-month plan; 3-, 6- and 12-month plans are prepaid
Refunds
All payments are final and non-refundable, except a partial refund if you are medically disqualified
No refunds once paid; a partial refund only after a medical disqualification
Early-exit fee
Not stated
None stated

Read off each seller’s own pages. altRX: September 28, 2026. Embody: October 25, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for altRX

8.8/10
  • Sells brand-name semaglutide pen and brand-name tirzepatide pen, which Embody does not price
  • Open FDA warning letter, June 8, 2026
Visit altRX

The case for Embody

9.3/10
Featured pick (affiliate partner)
  • No FDA warning letter on record
  • $120 a year less on compounded semaglutide injection
  • $240 a year less on compounded tirzepatide injection
  • Sells compounded oral tirzepatide, which altRX does not price
Visit Embody

Scores

altRX 8.8 · Embody 9.3 out of 10. Six weighted parts.

Value25%

10.0A
vs
B
10.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

6.0A
vs
B
9.0

Accessibility10%

10.0A
vs
B
10.0

Support10%

7.0A
vs
B
7.0

The score is the same formula for every seller. Payment does not enter it. Method

altRX vs Embody: questions

altRX has an open FDA warning letter dated June 8, 2026. Embody has none. Letters are matched to a seller by company, domain and address, never by a similar name.
altRX names four pharmacies. Embody names four pharmacies. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
Embody, by $120 a year at standing rates. altRX: $89 a month, about $1,068 a year. Embody: $79 a month, about $948 a year.
altRX states you can cancel at any time; refunds: all payments are final and non-refundable, except a partial refund if you are medically disqualified. Embody states you can cancel at any time; refunds: no refunds once paid; a partial refund only after a medical disqualification.
Embody is our featured pick on this page because it is an affiliate partner: we are paid if you sign up through our link. altRX pays us nothing. The scores are computed the same way for both and are shown as computed (altRX 8.8, Embody 9.3).

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks